FAKTOR-OPTIONSSCHEIN - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 20:49:13 28/06/2024 BST | ||
| 99.65 EUR | +1.61% |
|
| Current month | +140.93% | ||
| 1 month | +172.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 99.65 | +1.61% |
| 27/06/24 | 98.07 | +4.78% |
| 26/06/24 | 93.6 | -1.24% |
| 25/06/24 | 94.78 | +8.42% |
| 24/06/24 | 87.42 | +8.58% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 08:49 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SF3QWW |
| ISIN | DE000SF3QWW0 |
| Date issued | 20/08/2021 |
| Strike | 272.5 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.03 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 105.6 € |
|---|---|
| Lowest since issue | 0.4 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- Certificat
